Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIDA long-term safety extension of ontamalimab in ulcerative colitis or Crohn's disease
NL-OMON54678Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of ontamalimab in autoimmune colitis and Crohn's disease (2 arms), sponsored by Takeda. Primary endpoint: Primary safety and tolerability endpoint. Started Jan 2019; status: active, not recruiting.
02
Drugs
ontamalimab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON54678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54678.